These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 1389512)

  • 41. Oral granisetron for the prevention of acute late onset nausea and vomiting in patients treated with moderately emetogenic chemotherapy.
    Friedman CJ; Burris HA; Yocom K; Blackburn LM; Gruben D
    Oncologist; 2000; 5(2):136-43. PubMed ID: 10794804
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparative effects of intravenously administered alizapride and prochlorperazine in cisplatin-induced emesis.
    Roché H; Hyman G; Nahas G; Stoopler M; Ellison R; Desjardins R
    Cancer Invest; 1987; 5(2):89-93. PubMed ID: 3607576
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A randomized trial of high dose bolus metoclopramide versus low-dose continuous infusion metoclopramide in the prevention of cisplatin-induced emesis.
    Dana BW; McDermott M; Everts E; Abdulhay G
    Am J Clin Oncol; 1987 Jun; 10(3):253-6. PubMed ID: 3296733
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Controlling delayed vomiting: double-blind, randomized trial comparing placebo, dexamethasone alone, and metoclopramide plus dexamethasone in patients receiving cisplatin.
    Kris MG; Gralla RJ; Tyson LB; Clark RA; Cirrincione C; Groshen S
    J Clin Oncol; 1989 Jan; 7(1):108-14. PubMed ID: 2642536
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Tropisetron compared with a metoclopramide-based regimen in the prevention of chemotherapy-induced nausea and vomiting.
    Anderson H; Thatcher N; Howell A; Logan K; Sage T; de Bruijn KM
    Eur J Cancer; 1994; 30A(5):610-5. PubMed ID: 8080674
    [TBL] [Abstract][Full Text] [Related]  

  • 46. A randomised, double-blind comparison of granisetron with high-dose metoclopramide, dexamethasone and diphenhydramine for cisplatin-induced emesis. An NCI Canada Clinical Trials Group Phase III Trial.
    Warr D; Wilan A; Venner P; Pater J; Kaizer L; Laberge F; Latreille J; Stewart D; O'Connell G; Osoba D
    Eur J Cancer; 1992; 29A(1):33-6. PubMed ID: 1332737
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A comparison of granisetron as a single agent with conventional combination antiemetic therapies in the treatment of cytostatic-induced emesis. The Granisetron Study Group.
    Marty M
    Eur J Cancer; 1992; 28A Suppl 1():S12-6. PubMed ID: 1320913
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Efficacy and safety of casopitant mesylate, a neurokinin 1 (NK1)-receptor antagonist, in prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based highly emetogenic chemotherapy: a randomised, double-blind, placebo-controlled trial.
    Grunberg SM; Rolski J; Strausz J; Aziz Z; Lane S; Russo MW; Wissel P; Guckert M; Wright O; Herrstedt J
    Lancet Oncol; 2009 Jun; 10(6):549-58. PubMed ID: 19428297
    [TBL] [Abstract][Full Text] [Related]  

  • 49. A randomized, double-blind comparison of single-dose and divided multiple-dose dolasetron for cisplatin-induced emesis.
    Harman GS; Omura GA; Ryan K; Hainsworth JD; Cramer MB; Hahne WF
    Cancer Chemother Pharmacol; 1996; 38(4):323-8. PubMed ID: 8674154
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Randomised trial for the prevention of delayed emesis in patients receiving high-dose cisplatin.
    Matsui K; Fukuoka M; Takada M; Kusunoki Y; Yana T; Tamura K; Yoshida T; Iida K; Hirashima T; Tsukada H; Ushijima S; Miyawaki H; Masuda N
    Br J Cancer; 1996 Jan; 73(2):217-21. PubMed ID: 8546909
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Difference in persistence of efficacy of two antiemetic regimens on acute emesis during cisplatin chemotherapy. The Italian Group for Antiemetic Research.
    J Clin Oncol; 1993 Dec; 11(12):2396-404. PubMed ID: 8246029
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Metoclopramide versus metoclopramide and lorazepam. Superiority of combined therapy in the control of cisplatin-induced emesis.
    Gordon CJ; Pazdur R; Ziccarelli A; Cummings G; Al-Sarraf M
    Cancer; 1989 Feb; 63(3):578-82. PubMed ID: 2912533
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Antiemetic efficacy of dexamethasone. Randomized, double-blind, crossover study with prochlorperazine in patients receiving cancer chemotherapy.
    Markman M; Sheidler V; Ettinger DS; Quaskey SA; Mellits ED
    N Engl J Med; 1984 Aug; 311(9):549-52. PubMed ID: 6379459
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Tropisetron (Navoban) alone and in combination with dexamethasone in the prevention of chemotherapy-induced emesis: the Nordic experience.
    Sorbe BG
    Semin Oncol; 1994 Oct; 21(5 Suppl 9):20-6. PubMed ID: 9113123
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Research on antiemetics: an Italian model of success].
    Roila F
    Tumori; 1998; 84(1 Suppl):S3-11. PubMed ID: 9617377
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Efficacy & tolerability of ondansetron compared to metoclopramide in dose dependent cisplatin-induced delayed emesis.
    Bhatia A; Tripathi KD; Sharma M
    Indian J Med Res; 2004 Sep; 120(3):183-93. PubMed ID: 15489556
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative study of low-dose oral granisetron plus dexamethasone and high-dose metoclopramide plus dexamethasone in prevention of nausea and vomiting induced by CHOP-therapy in young patients with non-Hodgkin's lymphoma.
    Numbenjapon T; Sriswasdi C; Mongkonsritragoon W; Leelasiri A; Prayoonwiwat W
    J Med Assoc Thai; 2002 Nov; 85(11):1156-63. PubMed ID: 12546311
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Superiority of granisetron to dexamethasone plus prochlorperazine in the prevention of chemotherapy-induced emesis.
    Warr D; Willan A; Fine S; Wilson K; Davis A; Erlichman C; Rusthoven J; Lofters W; Osoba D; Laberge F
    J Natl Cancer Inst; 1991 Aug; 83(16):1169-73. PubMed ID: 1653363
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The oral NK(1) antagonist, aprepitant, given with standard antiemetics provides protection against nausea and vomiting over multiple cycles of cisplatin-based chemotherapy: a combined analysis of two randomised, placebo-controlled phase III clinical trials.
    de Wit R; Herrstedt J; Rapoport B; Carides AD; Guoguang-Ma J; Elmer M; Schmidt C; Evans JK; Horgan KJ
    Eur J Cancer; 2004 Feb; 40(3):403-10. PubMed ID: 14746859
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A randomized double-blind comparison of ondansetron and metoclopramide in the prophylaxis of emesis induced by cyclophosphamide, fluorouracil, and doxorubicin or epirubicin chemotherapy.
    Bonneterre J; Chevallier B; Metz R; Fargeot P; Pujade-Lauraine E; Spielmann M; Tubiana-Hulin M; Paes D; Bons J
    J Clin Oncol; 1990 Jun; 8(6):1063-9. PubMed ID: 2140854
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.